Hossein Asgarian-Omran

Single domain antibodies specific for HER2 dimerization domain effectively disrupts HER2 dimerization.

R. Valadan, M. Tehrani, Ahmad Najafi, 2023, International immunopharmacology.

Combination therapy of acute myeloid leukemia by dual PI3K/mTOR inhibitor BEZ235 and TLR-7/8 agonist R848 in murine model.

A. Ajami, Saeid Taghiloo, Hossein Asgarian-Omran, 2023, International immunopharmacology.

Cross‐talk between leukemic and immune cells at the tumor microenvironment in chronic lymphocytic leukemia: An update review

Saeid Taghiloo, Hossein Asgarian-Omran, 2024, European journal of haematology.

Glucose Metabolism in Acute Myeloid Leukemia Cell Line Is Regulated via Combinational PI3K/AKT/mTOR Pathway Inhibitors

Saeid Taghiloo, Mohsen Soltanshahi, Hossein Asgarian-Omran, 2023, Iranian journal of pharmaceutical research : IJPR.